Pluri Inc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Pluri's Short and Long Term Debt Total is relatively stable compared to the past year. As of 03/03/2025, Net Receivables is likely to grow to about 1 M, while Other Current Liabilities is likely to drop slightly above 2.3 M. Key indicators impacting Pluri's financial strength include:
The essential information of the day-to-day investment outlook for Pluri includes many different criteria found on its balance sheet. An individual investor should monitor Pluri's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Pluri.
Pluri competes with BioLineRx, Purple Biotech, Enlivex Therapeutics, Transgene, and Champions Oncology. Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. Pluri operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 154 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Pluri's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Pluri's current stock value. Our valuation model uses many indicators to compare Pluri value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pluri competition to find correlations between indicators driving Pluri's intrinsic value. More Info.
Pluri Inc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Pluri's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pluri by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Pluri Inc Systematic Risk
Pluri's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pluri volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Pluri Inc correlated with the market. If Beta is less than 0 Pluri generally moves in the opposite direction as compared to the market. If Pluri Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pluri Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pluri is generally in the same direction as the market. If Beta > 1 Pluri moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Pluri Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pluri's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Pluri growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Pluri help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pluri Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pluri Inc based on widely used predictive technical indicators. In general, we focus on analyzing Pluri Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pluri's daily price indicators and compare them against related drivers.
When running Pluri's price analysis, check to measure Pluri's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pluri is operating at the current time. Most of Pluri's value examination focuses on studying past and present price action to predict the probability of Pluri's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pluri's price. Additionally, you may evaluate how the addition of Pluri to your portfolios can decrease your overall portfolio volatility.